Switching between tofacitinib and baricitinib in alopecia areata: A review of clinical response

J Am Acad Dermatol. 2023 Dec;89(6):1248-1250. doi: 10.1016/j.jaad.2023.03.041. Epub 2023 Apr 5.

Authors

Ahmed Kazmi¹, Anthony Moussa², Laita Bokhari², Bevin Bhoyrul², Shobha Joseph², Vijaya Chitreddy², Samantha Eisman², Nekma Meah³, Rodney Sinclair⁴

Affiliations

¹ Sinclair Dermatology, East Melbourne, Victoria, Australia. Electronic address: ahmedkazmi@doctors.org.uk.
² Sinclair Dermatology, East Melbourne, Victoria, Australia.
³ St Helens and Knowsley Teaching Hospitals NHS Trust, Liverpool, England.
⁴ Sinclair Dermatology, East Melbourne, Victoria, Australia; The University of Melbourne, Melbourne, Victoria, Australia.

PMID: 37024053
DOI: 10.1016/j.jaad.2023.03.041

No abstract available

Publication types

Review

MeSH terms

Alopecia
Alopecia Areata* / drug therapy
Humans
Piperidines / therapeutic use

Substances

tofacitinib
baricitinib
Piperidines

Supplementary concepts

Diffuse alopecia